Last update 12 Aug 2025

KinoTeck Therapeutics Co., Ltd

Private Company|2021|Guangdong Sheng, China

Overview

Tags

Neoplasms
Small molecule drug
Chemical drugs

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms4
Top 5 Drug TypeCount
Small molecule drug3
Chemical drugs1
Top 5 TargetCount
FGFR2(Fibroblast growth factor receptor 2)2
SOS1(Son of sevenless homolog 1)1
p90 RSK(p90 RSK subfamily)1

Related

4
Drugs associated with KinoTeck Therapeutics Co., Ltd
HW071021
Target
SOS1
Mechanism
SOS1 inhibitors
Active Org.
Wuhan Humanwell Innovative Drug R & D Center Co., Ltd. [+2]
Originator Org.
Wuhan Humanwell Innovative Drug R & D Center Co., Ltd.
Active Indication
Advanced Malignant Solid Neoplasm [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
KNT-0916
Target
FGFR2
Mechanism
FGFR2 antagonists
Active Org.
KinoTeck Therapeutics Co., Ltd
Originator Org.
KinoTeck Therapeutics Co., Ltd
Active Indication
Solid tumor [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
BW-710
Target
FGFR2
Mechanism
FGFR2 antagonists
Active Org.
Shanghai Institute of Organic Chemistry, Chinese Academy of SciencesShanghai Institute of Organic Chemistry, Chinese Academy of Sciences [+2]
Originator Org.
KinoTeck Therapeutics Co., Ltd [+2]
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with KinoTeck Therapeutics Co., Ltd
NCT06800196
/ Not yet recruitingPhase 1
A Phase I, Multicenter, Open-label Study to Evaluate the Safety, Pharmacokinetics, Preliminary Efficacy of KNT-0916 in Subjects with Unresectable or Metastatic Solid Tumors with FGFR2 Alterations
100 Clinical Results associated with KinoTeck Therapeutics Co., Ltd
Login to view more data
0 Patents (Medical) associated with KinoTeck Therapeutics Co., Ltd
Login to view more data
100 Deals associated with KinoTeck Therapeutics Co., Ltd
Login to view more data
100 Translational Medicine associated with KinoTeck Therapeutics Co., Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
2
Preclinical
Phase 1
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
KNT-0916
 ( FGFR2 )		FGFR2 Mutation Solid Tumors
More
Phase 1
BW-710
 ( FGFR2 )		Neoplasms
More
Preclinical
HW071021
 ( SOS1 )		KRAS mutation-related tumors
More
Preclinical
WO2023236960
 ( p90 RSK )Patent Mining		Neoplasms
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free